CBP/p300 Degrader: A Promising Therapeutic Strategy for Treatment of Prostate Cancer and Beyond

被引：1
|
作者：
Hu, Jiankang [1 ,2 ]
Xu, Yong [1 ]
机构：
[1] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Ctr Chem Biol & Drug Discovery, Guangzhou 510530, Peoples R China
[2] Univ Chinese Acad Sci, Beijing 100049, Peoples R China
来源：
JOURNAL OF MEDICINAL CHEMISTRY | 2024年 / 67卷 / 07期
关键词：
CBP;
D O I：
10.1021/acs.jmedchem.4c00502
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Transcriptional coactivators CBP/p300 have emerged as potential targets for cancer therapeutics. This Viewpoint discusses recent results that demonstrate an exceptionally potent and orally efficacious CBP/p300 degrader for the treatment of prostate cancer. This degrader stands out as a promising new candidate for cancer therapy and deserves further research.
引用
收藏
页码：5272 / 5274
页数：3
相关论文
共 50 条
  • [1] Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia
    Wu, Tianbang
    Hu, Jiankang
    Zhao, Xiaofan
    Zhang, Cheng
    Dong, Ruibo
    Hu, Qingqing
    Xu, Hongrui
    Shen, Hui
    Zhang, Xiaohan
    Zhang, Yan
    Lin, Bin
    Wu, Xishan
    Xiang, Qiuping
    Xu, Yong
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (11) : 9194 - 9213
  • [2] Discovery of a Highly Potent PROTAC Degrader of p300/CBP Proteins for the Treatment of Enzalutamide-Resistant Prostate Cancer
    Ma, Mengjun
    Li, Mengyao
    Zhang, Chengwei
    Yang, Zixuan
    Chen, Xiaoyu
    Lu, Penghui
    Nie, Shuangshuang
    Zhang, Siqi
    Ma, Shumin
    Qin, Chong
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (19) : 17290 - 17318
  • [3] The important role of the histone acetyltransferases p300/CBP in cancer and the promising anticancer effects of p300/CBP inhibitors
    Wu, Xin
    Zhang, Xin
    Tang, Shaoshan
    Wang, Yao
    CELL BIOLOGY AND TOXICOLOGY, 2025, 41 (01)
  • [4] Therapeutic targeting of the p300/CBP bromodomain for the treatment of castration-resistant prostate cancer.
    Brooks, Nigel
    Pegg, Neil
    Worthington, Jenny
    Young, Barbara
    Prosser, Amy
    CANCER RESEARCH, 2018, 78 (16) : 74 - 75
  • [5] p300/CBP and cancer
    Narayanan Gopalakrishna Iyer
    Hilal Özdag
    Carlos Caldas
    Oncogene, 2004, 23 : 4225 - 4231
  • [6] p300/CBP and cancer
    Iyer, NG
    Özdag, H
    Caldas, C
    ONCOGENE, 2004, 23 (24) : 4225 - 4231
  • [7] Targeting AR positive prostate cancer cells by the novel P300/CBP oral available PROTAC degrader
    Luo, Jie
    Prolia, Abhijit
    Qiao, Yuanyuan
    Tian, Jean
    Mannan, Rahul
    Mahapatra, Somnath
    Chen, Zhixiang
    Seri, Rithvik
    Wang, Shaomeng
    Chinnaiyan, Arul
    CANCER RESEARCH, 2024, 84 (06)
  • [8] The coactivators CBP and p300 in androgen independent prostate cancer
    Debes, JD
    Culig, Z
    Tindall, DJ
    HORMONAL CARCINOGENESIS IV, 2005, : 494 - 500
  • [9] Targeting the p300/CBP Axis in Lethal Prostate Cancer
    Welti, Jonathan
    Sharp, Adam
    Brooks, Nigel
    Yuan, Wei
    McNair, Christopher
    Chand, Saswati N.
    Pal, Abhijit
    Figueiredo, Ines
    Riisnaes, Ruth
    Gurel, Bora
    Rekowski, Jan
    Bogdan, Denisa
    West, William
    Young, Barbara
    Raja, Meera
    Prosser, Amy
    Lane, Jordan
    Thomson, Stuart
    Worthington, Jenny
    Onions, Stuart
    Shannon, Jonathan
    Paoletta, Silvia
    Brown, Richard
    Smyth, Don
    Harbottle, Gareth W.
    Gil, Veronica S.
    Miranda, Susana
    Crespo, Mateus
    Ferreira, Ana
    Pereira, Rita
    Tunariu, Nina
    Carreira, Suzanne
    Neeb, Antje J.
    Ning, Jian
    Swain, Amanda
    Taddei, David
    Schiewer, Matthew J.
    Knudsen, Karen E.
    Pegg, Neil
    de Bono, Johann S.
    CANCER DISCOVERY, 2021, 11 (05) : 1118 - 1137
  • [10] Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents
    Chen, Qingjuan
    Yang, Binhui
    Liu, Xiaochen
    Zhang, Xu D.
    Zhang, Lirong
    Liu, Tao
    THERANOSTICS, 2022, 12 (11): : 4935 - 4948
12345